Vor Biopharma (NYSE:VOR) Price Target Lowered to $13.00 at HC Wainwright

Vor Biopharma (NYSE:VOR) had its target price trimmed by HC Wainwright from $17.50 to $13.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the company. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Vor Biopharma in a report on Thursday. Stifel Nicolaus dropped their price target on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday. Finally, JMP Securities restated a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Vor Biopharma presently has a consensus rating of “Buy” and a consensus price target of $8.86.

Vor Biopharma Stock Performance

Shares of VOR opened at $0.87 on Friday. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $2.43. The company’s 50-day simple moving average is $1.22 and its 200-day simple moving average is $1.01. The stock has a market capitalization of $59.75 million, a PE ratio of -0.53 and a beta of -0.40.

Institutional Trading of Vor Biopharma

Several large investors have recently modified their holdings of VOR. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at about $33,000. Virtu Financial LLC bought a new stake in Vor Biopharma in the fourth quarter valued at $60,000. XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the fourth quarter worth approximately $80,000. Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma during the 4th quarter worth $102,000. Finally, Northern Trust Corp lifted its holdings in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares during the period. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.